Natera announces evidence for Prospera test at 2026 ISHLT

Natera (NTRA) announced a broad body of evidence supporting its Prospera test at the 2026 International Society for Heart and Lung Transplantation, ISHLT, Annual Meeting. In heart transplant: Prospera Heart serial dynamics predicted a variety of adverse outcomes at 1-year post-transplant, in addition to rejection. Patients with a positive Prospera result were up to 4x more likely to experience adverse outcomes by 1-year post-transplant and Prospera outperformed biopsy in detecting many of these outcomes. Real-world clinical impact: in more than 30% of cases, Prospera results influenced physician decisions related to immunosuppression or biopsy, demonstrating clinical utility beyond just identifying acute rejection. New independent validation solidifies the excellent performance of Prospera Heart with DQS, preserving high sensitivity while reducing false positives by 30% compared to donor fraction alone. In lung transplant: Data from multiple abstracts highlight the ability of Prospera Lung to detect infection, chronic lung allograft dysfunction, and early signs of graft damage, including scenarios where such complications were undetected on biopsy. While the standard cutoff for a Prospera-positive result is 1%, many studies have shown that significantly increased Prospera results, defined as extreme molecular injury, convey even higher risk of CLAD and mortality. New data suggests that a preemptive treatment approach to identify EMI can lead to improved patient outcomes, including forced expiratory volume in 1 second